EU regulator backs AstraZeneca and Daiichi's lung cancer drug (updated)
15/09/2023 15:38
(Recasts lede, adds details in paragraph 2,3, 4)
Sept 15 (Reuters) - AstraZeneca AZN.L said on Friday
its and Daiichi Sankyo's 4568.T cancer drug Enhertu was
recommended by the European Medicines Agency's human medicines
committee as a monotherapy to treat patients with a type of
non-small cell lung cancer (NSCLC).
The recommendation is based on the mid-stage data that
showed Enhertu reduced the tumour by 49% and the median duration
of response by 16.8 months in patients previously treated for
lung cancer.
The drug is
already approved
in the European Union as a treatment for patients with an
advanced form of breast cancer.
Recommendations made by the human medicines committee
will have to be formally approved by the European Commission.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shilpi
Majumdar nad Shweta Agarwal)
((Khushi.Mandowara@thomsonreuters.com;))